SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
SELLAS Life Sciences Dividend Announcement
• SELLAS Life Sciences announced a semi annually dividend of $0.00 per ordinary share which will be made payable on 2010-12-20. Ex dividend date: 2010-12-09
• SELLAS Life Sciences's trailing twelve-month (TTM) dividend yield is -%
SELLAS Life Sciences Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2010-12-09 | $0.00 | semi annually | 2010-12-20 |
2010-09-09 | $0.00 | semi annually | 2010-09-22 |
SELLAS Life Sciences Dividend per year
SELLAS Life Sciences Dividend Yield
SELLAS Life Sciences current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing SELLAS Life Sciences stock? Use our calculator to estimate your expected dividend yield:
SELLAS Life Sciences Financial Ratios
SELLAS Life Sciences Dividend FAQ
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Place an order: Use the brokerage's trading platform to place an order to buy SELLAS Life Sciences stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.